Skip to main content
OpenTrials

Clinical trial condition

Recurrent Renal Cell Carcinoma

Explore clinical trials studying Recurrent Renal Cell Carcinoma. Study availability and eligibility vary by location and protocol.

30 public trials 1 recruiting study
Refine in advanced search Browse all conditions

Recurrent Renal Cell Carcinoma trial results

Completed

Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer

NCT01727076

Conditions
Adenocarcinoma, Bronchial Neoplasms, Carcinoma, +47 more
Locations
  • Stanford Cancer Institute Palo Alto Palo Alto, California, United States
  • National Institutes of Health Clinical Center Bethesda, Maryland, United States
  • University of Minnesota/Masonic Cancer Center Minneapolis, Minnesota, United States
  • Seattle Cancer Care Alliance Seattle, Washington, United States
View Trial Details
Completed

A Study of RO4929097 in Patients With Advanced Renal Cell Carcinoma That Have Failed Vascular Endothelial Growth Factor (VEGF)/Vascular Endothelial Growth Factor Receptor (VEGFR) Therapy

NCT01141569

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +16 more
Locations
  • BCCA-Vancouver Cancer Centre Vancouver, British Columbia, Canada
  • London Regional Cancer Program London, Ontario, Canada
  • Ottawa Health Research Institute-General Division Ottawa, Ontario, Canada
  • University Health Network-Princess Margaret Hospital Toronto, Ontario, Canada
View Trial Details
Completed

Cediranib Maleate in Treating Patients With Recurrent or Metastatic Kidney Cancer That Cannot Be Removed By Surgery

NCT00227760

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +15 more
Locations
  • Cross Cancer Institute Edmonton, Alberta, Canada
  • BCCA-Vancouver Cancer Centre Vancouver, British Columbia, Canada
  • Juravinski Cancer Centre at Hamilton Health Sciences Hamilton, Ontario, Canada
  • London Regional Cancer Program London, Ontario, Canada
View Trial Details
Completed

Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer

NCT00126503

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +19 more
Locations
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
  • Dana-Farber Harvard Cancer Center Boston, Massachusetts, United States
  • Beth Israel Deaconess Medical Center Boston, Massachusetts, United States
  • University of Pennsylvania/Abramson Cancer Center Philadelphia, Pennsylvania, United States
View Trial Details

Related conditions